Agreed. I assume covid restrictions and subsequent issues with the hospital system have impacted clinical trials. I am really surprised we haven’t received a “first patient treated” announcement for the DFU trial, as this is a condition that is genuinely not elective.
Not holding my breath, however some comments from Ross in the quarterly about how the current environment is impacting the trials would be well received by the market.
Issues with communication aside, I just can’t see how Cynata is at this market cap with the following known catalysts:
ARDS enrolment complete + results (Q1)
DFU 1st patient enrolled (Q1)
GVHD IND, trial structure and start (Q1 + Q2)
IPF Samuels pre-clinical dosing data (Q1 or Q2)
CYP chart, page-1684
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
-0.010(3.70%) |
Mkt cap ! $46.97M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.5¢ | $23.84K | 92.58K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10800 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 24939 | 1 |
View Market Depth
| Last trade - 14.33pm 09/10/2024 (20 minute delay) ? |
| CYP (ASX) Chart |